

**Factors for Consideration in the Development of a Blind In Vitro  
Quality Assurance Program**

Timothy J. Donovan, Brian J. Lawson, Jane M. Tapio, Dr. Richard J. Winslow

Lockheed Martin Corporation  
PO Box 1072, Schenectady, NY 12301

**ABSTRACT**

Facilities that subcontract invitro bioassay analysis should develop a program for adequate tracking of subcontractor performance. This paper provides an overview of a quality assurance program which has proven to be successful over a number of years for the tracking of subcontractor performance. This document includes issues for consideration (e.g. pooling urine), concepts for tracking (e.g. control charts), etc. A review of related issues in ANSI N13.30 and ANSI 42.2 is also included.